MedPath

Research on a New Intelligent Mobile Screening and Diagnosis Pattern for Ocular Diseases

Not yet recruiting
Conditions
Ophthalmic Diseases (Specific Types Not Restricted)
Cataract
Refraction Error
Diabetic Retinopathy (DR)
Age Related Macular Degeneration (ARMD)
Registration Number
NCT07003165
Lead Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Brief Summary

The global distribution of primary ophthalmic medical resources is uneven, and the traditional eye disease screening model has problems such as low efficiency, high cost and limited coverage. With the development of artificial intelligence and other technologies, it provides technical support for the construction of intelligent mobile screening model for eye diseases. The investigator's team has developed the 5G intelligent ophthalmic vehicle and served tens of thousands of people in 108 cities nationwide, initially verifying the feasibility of the new intelligent mobile screening model. However, the application effect, acceptance and influencing factors of this model in different regions are not clear, and there is a lack of economic benefit analysis based on real-world data. In this study, the investigators will conduct a cross-sectional study of large-scale population screening for blinding eye diseases in grassroots areas through the smart mobile screening model, focusing on the screening effectiveness and cost-effectiveness of the smart mobile screening model, integrating real-world multimodal eye health data, developing multiple smart screening analysis models, and exploring its adaptability and direction of improvement in grassroots areas.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
15000
Inclusion Criteria
  • Age ≥ 7 years
  • Voluntary informed consent
Exclusion Criteria

-Inability to complete the required examinations with the help of others due to old age, infirmity, poor general condition, etc.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cost-effectivenessBaseline,6months,12months

Incremental Cost per True Positive Case Detected

Secondary Outcome Measures
NameTimeMethod
Eye disease detection rateBaseline,6months,12months
Accuracy of multiple intelligent screening analysis modelsBaseline
Screening participation ratebaseline
© Copyright 2025. All Rights Reserved by MedPath